Related Experiment Video
Updated: Apr 30, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Emerging therapeutic options for eosinophilic esophagitis
Timothy Dougherty1, Sindu Stephen1, Marie L Borum1
1Dr Dougherty is a fellow and Dr Borum is a professor of medicine and chair in the Division of Gastroenterology and Liver Diseases at The George Washington University in Washington, DC. Both doctors are also affiliated with The George Washington University Medical Faculty Associates. Dr Stephen is an office-based gastroenterologist in Silver Spring, Maryland. Dr Doman is a clinical professor of medicine at The George Washington University.
Eosinophilic esophagitis (EoE) is a chronic allergic esophageal disease. Current treatments include corticosteroids, with newer therapies like biologics under investigation, offering hope for better management.
Area of Science:
- Gastroenterology
- Allergy Immunology
Background:
- Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease.
- Often observed in atopic individuals, EoE presents a relapsing-remitting course.
- Current management includes pharmacotherapy, dietary changes, and endoscopic interventions.
Purpose of the Study:
- To review current and emerging therapeutic strategies for eosinophilic esophagitis.
- To explore the role of allergic mechanisms in EoE etiology and treatment.
Main Methods:
- Literature review of current management and investigational therapies for EoE.
- Analysis of the role of immunoglobulin E (IgE)-mediated reactions in EoE.
Main Results:
- Corticosteroids remain the primary pharmacotherapy for EoE.
- Investigational treatments include immunomodulators, leukotriene antagonists, biologics, and monoclonal antibodies.
- The involvement of IgE-mediated allergic reactions is increasingly recognized.
Conclusions:
- Effective management of EoE requires a multi-faceted approach.
- Emerging therapies targeting allergic pathways show promise for EoE treatment.
- Understanding IgE's role may lead to novel therapeutic targets for eosinophilic esophagitis.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:

